Samsung Bioepis First to Obtain European Commission Approval for a Third AntiTNF Biosimilar with Imraldi adalimumab

Samsung Bioepis Co. Ltd. today announced the European Commissions EC approval of Imraldi a biosimilar referencing Humira 1 adalimumab for the treatment of rheumatoid arthritis juvenile idiopathic arthritis axial spondyloarthritis ...